MedTrace Logo

Study of Activated CIK Armed With Bispecific Antibody for Advanced Liver Cancer

NCT03146637 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 80

Last updated 2021-02-01

No results posted yet for this study

Summary

This is a phase II Randomized comparison clinical trial of activated CIK armed with anti-CD3-MUC1/CEA/EpCAM/GPC3 bispecific antibody for advanced liver cancer. And the aim of this research is to study the clinical efficacy and safety of activated CIK armed with anti-CD3-MUC1/CEA/EpCAM/GPC3 bispecific antibody for liver cancer.

Conditions

Interventions

BIOLOGICAL

Activated CIK

Activated CIK armed with bispecific antibody were infused for 3 days，after 2 days，bispecific antibody was infused separately for 3 days

BIOLOGICAL

CIK

Traditional CIK were infused for 3 days

Sponsors & Collaborators

  • Beijing 302 Hospital

    collaborator OTHER

  • Benhealth Biopharmaceutical (Shenzhen) Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Yinying Lu, Doctor · Liver Cancer Diagnosis & Treatment and Research Center of 302 Military Hospital of China

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-05-01
Primary Completion
2021-01-27
Completion
2021-01-28

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03146637 on ClinicalTrials.gov